Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer

Anna Bill-Axelson, M.D., Ph.D., Lars Holmberg, M.D., Ph.D., Hans Garmo, Ph.D., Jennifer R. Rider, Sc.D., Kimmo Taari, M.D., Ph.D., Christer Busch, M.D., Ph.D., Stig Nordling, M.D., Ph.D., Michael Häggman, M.D., Ph.D., Swen-Olof Andersson, M.D., Ph.D., Anders Spångberg, M.D., Ph.D., Ove Andrén, M.D., Ph.D., Juni Palmgren, Ph.D., Gunnar Steineck, M.D., Ph.D., Hans-Olov Adami, M.D., Ph.D., and Jan-Erik Johansson, M.D., Ph.D.

Abstract

Background
Radical prostatectomy reduces mortality among men with localized prostate cancer; however, important questions regarding long-term benefit remain.

Methods
Between 1989 and 1999, we randomly assigned 695 men with early prostate cancer to watchful waiting or radical prostatectomy and followed them through the end of 2012. The primary end points in the Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) were death from any cause, death from prostate cancer, and the risk of metastases. Secondary end points included the initiation of androgen-deprivation therapy.

Results
During 23.2 years of follow-up, 200 of 347 men in the surgery group and 247 of the 348 men in the watchful-waiting group died. Of the deaths, 63 in the surgery group and 99 in the watchful-waiting group were due to prostate cancer; the relative risk was 0.56 (95% confidence interval [CI], 0.41 to 0.77; \( P = 0.001 \)), and the absolute difference was 11.0 percentage points (95% CI, 4.5 to 17.5). The number needed to treat to prevent one death was 8. One man died after surgery in the radical-prostatectomy group. Androgen-deprivation therapy was used in fewer patients who underwent prostatectomy (a difference of 25.0 percentage points; 95% CI, 17.7 to 32.3). The benefit of surgery with respect to death from prostate cancer was largest in men younger than 65 years of age (relative risk, 0.45) and in those with intermediate-risk prostate cancer (relative risk, 0.38). However, radical prostatectomy was associated with a reduced risk of metastases among older men (relative risk, 0.68; \( P = 0.04 \)).

Conclusions
Extended follow-up confirmed a substantial reduction in mortality after radical prostatectomy; the number needed to treat to prevent one death continued to decrease when the treatment was modified according to age at diagnosis and tumor risk. A large proportion of long-term survivors in the watchful-waiting group have not required any palliative treatment. (Funded by the Swedish Cancer Society and others.)
The Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4), a randomized trial of radical prostatectomy versus watchful waiting in men with localized prostate cancer diagnosed before the era of prostate-specific antigen (PSA) testing, showed a survival benefit of radical prostatectomy as compared with observation at 15 years of follow-up.1 By contrast, the Prostate Cancer Intervention Versus Observation Trial (PIVOT), initiated in the early era of PSA testing, showed that radical prostatectomy did not significantly reduce prostate cancer–specific or overall mortality after 12 years.2 PSA screening profoundly changes the clinical domain of study. Among other considerations, the substantial additional lead time necessitates very long follow-up periods in the PIVOT trial to determine the effect of surgery as compared with observation. In the meantime, the SPCG-4 offers insight regarding the effectiveness of radical prostatectomy and the natural history of prostate cancer.

In an 18-year follow-up of SPCG-4, an accumulating number of events permitted analyses stratified according to age and tumor risk. Furthermore, we examined the prevalence of metastases and the use of palliative treatments to estimate the long-term disease burden according to study group.

**METHODS**

**Patients**

Between October 1989 and December 1999, at 14 centers in Sweden, Finland, and Iceland, we randomly assigned 695 men with localized prostate cancer to either radical prostatectomy or watchful waiting, as described in previous articles,1,3,4 and in the study protocol (www.cancercentrum.se). The study was approved by the regional ethics committee for each participating center, and oral informed consent was obtained from all patients. All authors vouch for the accuracy and completeness of the data, and the last author vouches for the adherence of the study to the protocol.

Men were eligible for inclusion in the study if they were younger than 75 years of age and had a life expectancy of more than 10 years, had no other known cancers, and had a localized tumor of stage T0d (later named T1b), T1, or T2, as defined by the 1978 criteria of the International Union against Cancer. After the revision of staging criteria in 1987, T1c tumors were also included, starting in 1994.5 Tumors had to be well differentiated to moderately well differentiated, according to the World Health Organization (WHO) classification, on the basis of core biopsies or fine-needle aspiration. All patients included in the study were required to have a serum PSA level of less than 50 ng per milliliter and a negative bone scan.

**Study Design**

In men assigned to the radical-prostatectomy group, the surgical procedure started with a lymphadenectomy of the obturator fossa.6 If no nodal metastases were detected in frozen sections, the radical prostatectomy was performed.7 Radical excision of the tumor was given priority over nerve-sparing surgery. Men who were assigned to observation did not receive any immediate treatment.

If signs of local recurrence (a palpable nodule or histologically confirmed recurrence) developed in a patient in the radical-prostatectomy group, androgen-deprivation therapy was initiated. Men in the watchful-waiting group who had signs of obstructive voiding were treated with transurethral resection. Confirmed metastases (detected by means of bone scans) were treated with hormone therapy. In 2003, clinicians were allowed to initiate androgen-deprivation treatment if there were signs of tumor progression or an increasing PSA level or if they believed that hormone therapy would provide a clinical benefit. In 1999, all core biopsy specimens were reviewed by four uropathologists and graded according to the Gleason system.8 (Before 2005, the Gleason score was the sum of the two most common histologic patterns or grades in a prostate tumor, each of which is graded on a scale of 1 to 5, with 5 indicating the most aggressive pattern.)

Patients were followed every 6 months for 2 years and annually thereafter. At the last monitoring rounds, men who were unable to attend the clinic were followed from nursing homes or by their general practitioner with the use of PSA monitoring. Initially, bone scans were obtained annually, but after 2003, they were obtained every second year. Distant metastases were considered to be present when bone scans, skeletal radiographs, computed tomographic scans, or chest radiographs showed metastases or if lymph nodes at sites other than the regional sites showed cytologic or histologic evidence of
prostate cancer. In the radical-prostatectomy group, local recurrence was defined as the presence of a palpable mass on digital rectal examination or a histologically confirmed tumor on rectal biopsy. In the watchful-waiting group, tumor progression was defined as palpable extracapsular extension or symptoms of obstructive voiding that required intervention.

In patients who died, an independent end-point committee whose members were unaware of the study-group assignments determined the cause of death on the basis of information extracted from the patients’ medical records. The committee members used a protocol that defined disease progression according to increases in PSA levels, local recurrence, the occurrence of metastases, and the need for androgen-deprivation therapy and palliative treatments. Each member of the end-point committee determined the cause of death; in cases in which there was disagreement among the members regarding the cause of death, the committee met to reach consensus. All participants were followed until December 31, 2012, and none of the patients were lost to follow-up.

**STATISTICAL ANALYSIS**

Analyses have been performed every third year according to the protocol. The primary end points were death from any cause, death from prostate cancer (with death from other causes treated as a competing risk), and risk of metastases, and the need for androgen-deprivation therapy and palliative treatments. Each member of the end-point committee determined the cause of death; in cases in which there was disagreement among the members regarding the cause of death, the committee met to reach consensus. All participants were followed until December 31, 2012, and none of the patients were lost to follow-up.

We used Gray’s test to assess treatment effects. Effect sizes were quantified both by analyzing relative risks with 95% confidence intervals and by determining differences in cumulative incidence (with 95% confidence intervals). Relative risks were estimated with the use of Cox proportional-hazards models in cases in which proportionality was verified by means of visual inspection of the parallelisms of the logarithms of the estimated cumulative incidence. A cumulative incidence approach was used to account for competing risks among various causes of death.

To assess the possible modification of the treatment effect, analyses were stratified according to the patient’s age at diagnosis (<65 years vs. ≥65 years) and tumor risk. The subgroup analyses were not included in the main protocol but were specified before the data were reviewed. Risk groups were defined with the use of Gleason scores from the pathological review as follows: low risk, PSA level less than 10 and either a Gleason score of less than 7 or WHO grade 1 (on a scale of 1 to 3, with higher grades indicating more aggressive disease) in tumors that were diagnosed only by means of cytologic assessment; high risk, PSA level of 20 or higher or a Gleason score greater than 7; and intermediate risk, all patients who did not fulfill the criteria for low or high risk. The modification of the effect of radical prostatectomy was tested in the Cox proportional-hazards model by including an interaction term between the subgroup category and randomization group.

The prevalence of the use of palliative treatment was calculated at every other year of follow-up, ending at 18 years after randomization. Palliative treatment was androgen-deprivation treatment (antiandrogen therapy or gonadotropin-releasing hormone analogues or orchiectomy) in patients with or without verified metastases and in patients with metastases who had received other palliative treatment (external or internal palliative radiation therapy, laminectomy, or chemotherapy drugs).

**RESULTS**

A total of 347 men were randomly assigned to the radical-prostatectomy group, and 348 men were assigned to the watchful-waiting group. The baseline characteristics of the two groups were similar; the mean age of the men in both groups was 65 years. Only 12% of the patients had nonpalpable T1c tumors at the time of enrollment in the study. The mean PSA level was approximately 13 ng per milliliter (Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org). By December 31, 2012, a total of 294 men in the radical-prostatectomy group had undergone a radical prostatectomy, and 294 men in the watchful-waiting group had not received curative treatment. In the radical-prostatectomy group, 23 patients (16 pa-
A Radical Prostatectomy

All Patients

No. at Risk 347 339 311 271 236 168 87

Age <65 Yr

No. at Risk 157 154 145 136 124 96 60

Age ≥65 Yr

No. at Risk 190 185 166 135 112 72 27

Low Risk

No. at Risk 118 115 110 99 89 72 40

Intermediate Risk

No. at Risk 148 144 132 114 100 68 33

High Risk

No. at Risk 81 80 69 58 47 28 14

B Watchful Waiting

All Patients

No. at Risk 348 334 306 251 211 143 61

Age <65 Yr

No. at Risk 166 157 144 118 102 75 34

Age ≥65 Yr

No. at Risk 182 177 162 133 109 68 27

Low Risk

No. at Risk 131 128 122 109 95 66 31

Intermediate Risk

No. at Risk 133 126 113 91 75 55 18

High Risk

No. at Risk 84 80 71 51 41 22 12

Other cause of death, without androgen-deprivation therapy

Other cause of death, with metastases

Other cause of death, with androgen-deprivation therapy

Death from prostate cancer

The New England Journal of Medicine

Downloaded from nejm.org by BRADFORD KNEY on March 23, 2014. For personal use only. No other uses without permission. Copyright © 2014 Massachusetts Medical Society. All rights reserved.
Table 1. Cumulative Incidence, Absolute Risk Reduction, and Relative Risk of Death from Any Cause, Death from Prostate Cancer, and Development of Distant Metastases at 18 Years of Follow-up.*

<table>
<thead>
<tr>
<th>End Point</th>
<th>Cumulative Incidence</th>
<th>Absolute Risk Reduction with Radical Prostatectomy</th>
<th>Relative Risk with Radical Prostatectomy (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Radical Prostatectomy (N = 347)</td>
<td>Watchful Waiting (N = 348)</td>
<td>percentage points (95% CI)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>no. of events</td>
<td>% (95% CI)</td>
<td>no. of events</td>
<td>% (95% CI)</td>
</tr>
<tr>
<td>Death from any cause</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>200</td>
<td>56.1 (50.9 to 62.0)</td>
<td>247</td>
<td>68.9 (63.8 to 74.3)</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;65 yr</td>
<td>69</td>
<td>40.0 (32.7 to 49.0)</td>
<td>112</td>
<td>65.6 (58.2 to 73.9)</td>
</tr>
<tr>
<td>≥65 yr</td>
<td>131</td>
<td>69.8 (63.1 to 77.4)</td>
<td>135</td>
<td>71.7 (64.9 to 79.3)</td>
</tr>
<tr>
<td>Tumor risk</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>51</td>
<td>43.4 (34.8 to 54.1)</td>
<td>85</td>
<td>59.1 (50.7 to 68.8)</td>
</tr>
<tr>
<td>Intermediate</td>
<td>87</td>
<td>57.1 (49.0 to 66.4)</td>
<td>95</td>
<td>72.5 (64.5 to 81.6)</td>
</tr>
<tr>
<td>High</td>
<td>62</td>
<td>73.3 (63.8 to 84.2)</td>
<td>67</td>
<td>78.8 (69.7 to 89.2)</td>
</tr>
<tr>
<td>Death from prostate cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>63</td>
<td>17.7 (14.0 to 22.4)</td>
<td>99</td>
<td>28.7 (24.2 to 34.2)</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;65 yr</td>
<td>31</td>
<td>18.3 (13.1 to 25.7)</td>
<td>58</td>
<td>34.1 (27.3 to 42.5)</td>
</tr>
<tr>
<td>≥65 yr</td>
<td>32</td>
<td>17.3 (12.5 to 24.0)</td>
<td>41</td>
<td>23.9 (18.2 to 31.5)</td>
</tr>
<tr>
<td>Tumor risk</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>11</td>
<td>10.2 (5.8 to 18.0)</td>
<td>20</td>
<td>14.0 (9.1 to 21.5)</td>
</tr>
<tr>
<td>Intermediate</td>
<td>24</td>
<td>15.1 (10.2 to 22.2)</td>
<td>50</td>
<td>39.3 (31.3 to 49.3)</td>
</tr>
<tr>
<td>High</td>
<td>28</td>
<td>33.1 (24.0 to 45.7)</td>
<td>29</td>
<td>35.7 (26.3 to 48.5)</td>
</tr>
<tr>
<td>Distant metastases</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>89</td>
<td>26.1 (21.7 to 31.4)</td>
<td>138</td>
<td>38.3 (33.4 to 44.0)</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;65 yr</td>
<td>45</td>
<td>28.7 (22.2 to 37.1)</td>
<td>76</td>
<td>44.5 (37.3 to 53.0)</td>
</tr>
<tr>
<td>≥65 yr</td>
<td>44</td>
<td>23.8 (18.4 to 30.9)</td>
<td>62</td>
<td>32.7 (26.4 to 40.5)</td>
</tr>
<tr>
<td>Tumor risk</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>15</td>
<td>13.6 (8.4 to 21.9)</td>
<td>35</td>
<td>24.2 (17.8 to 33.0)</td>
</tr>
<tr>
<td>Intermediate</td>
<td>37</td>
<td>25.0 (18.8 to 33.3)</td>
<td>59</td>
<td>44.9 (36.9 to 54.7)</td>
</tr>
<tr>
<td>High</td>
<td>37</td>
<td>45.9 (35.8 to 58.8)</td>
<td>44</td>
<td>50.8 (40.6 to 63.5)</td>
</tr>
<tr>
<td>Androgen-deprivation therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>145</td>
<td>42.5 (37.5 to 48.1)</td>
<td>235</td>
<td>67.4 (62.6 to 72.6)</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;65 yr</td>
<td>68</td>
<td>44.2 (36.9 to 53.0)</td>
<td>122</td>
<td>72.6 (66.0 to 79.8)</td>
</tr>
<tr>
<td>≥65 yr</td>
<td>77</td>
<td>40.9 (34.4 to 48.7)</td>
<td>113</td>
<td>62.8 (56.0 to 70.4)</td>
</tr>
<tr>
<td>Tumor risk</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>32</td>
<td>27.9 (20.7 to 37.6)</td>
<td>63</td>
<td>47.9 (39.9 to 57.5)</td>
</tr>
<tr>
<td>Intermediate</td>
<td>65</td>
<td>44.9 (37.4 to 54.0)</td>
<td>98</td>
<td>73.6 (66.3 to 81.7)</td>
</tr>
<tr>
<td>High</td>
<td>48</td>
<td>59.3 (49.3 to 71.2)</td>
<td>74</td>
<td>88.1 (81.2 to 95.6)</td>
</tr>
</tbody>
</table>

* CI denotes confidence interval.
tients in the high-risk group, 7 patients in the intermediate-risk group, and no patients in the low-risk group) had lymph node–positive disease and thus did not undergo radical prostatectomy (Fig. S1 in the Supplementary Appendix). The median follow-up time was 13.4 years (range, 3 weeks to 23.2 years).

**Mortality**

A total of 447 of the 695 men enrolled in the study (64%) had died by the end of 2012. This total included 200 men in the radical-prostatectomy group and 247 men in the watchful-waiting group. The cumulative incidence of death at 18 years was 56.1% in the radical-prostatectomy group and 68.9% in the watchful-waiting group (a difference of 12.7 percentage points; 95% confidence interval [CI], 5.1 to 20.3), corresponding to a relative risk of death in the radical-prostatectomy group of 0.71 (95% CI, 0.59 to 0.86; P<0.001) (Fig. 1 and Tables 1 and 2). The number needed to treat to prevent one death at 18 years of follow-up was 8. One man in the radical-prostatectomy group died after surgery.

By the end of 2012, a total of 63 men in the radical-prostatectomy group and 99 men in the watchful-waiting group had died from prostate cancer. The cumulative incidence of death from prostate cancer at 18 years was 17.7% in the radical-prostatectomy group and 28.7% in the watchful-waiting group (a difference of 11.0 percentage points; 95% CI, 4.5 to 17.5), corresponding to a relative risk of death in the radical-prostatectomy group of 0.56 (95% CI, 0.41 to 0.77; P = 0.001) (Fig. 1 and Tables 1 and 2). The difference in mortality continued to increase from 9.6 deaths per 1000 person-years during 5 to 10 years of follow-up to 24.5 deaths per 1000 person-years in the 15-to-20-year follow-up interval.

In both older and younger men, death from other causes without evidence of metastases or the use of androgen-deprivation therapy was more common in the radical-prostatectomy group than in the watchful-waiting group (Fig. 1).

**Distant Metastases**

Distant metastases were diagnosed in 89 men in the radical-prostatectomy group and in 138 men in the watchful-waiting group. The cumulative incidence of distant metastases at 18 years of follow-up was 26.1% in the radical-prostatectomy group and 38.3% in the watchful-waiting group.

### Table 2. Cause of Death According to Study Group, Age at Diagnosis, and Tumor Risk.^

<table>
<thead>
<tr>
<th>Cause of Death</th>
<th>Radical Prostatectomy (N = 347)</th>
<th>Watchful Waiting (N = 348)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Men</td>
<td>Age &lt;65 yr</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>11</td>
<td>3</td>
</tr>
<tr>
<td>Other cause</td>
<td>107</td>
<td>32</td>
</tr>
<tr>
<td>Without metastasis but with local progression or recurrence</td>
<td>14</td>
<td>2</td>
</tr>
<tr>
<td>With metastasis</td>
<td>11</td>
<td>4</td>
</tr>
<tr>
<td>With unknown status regarding metastasis</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>Within first month after randomization</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Any cause</td>
<td>200</td>
<td>69</td>
</tr>
</tbody>
</table>

^

All events were evaluated by the dependent end-point committee.
(a difference of 12.2 percentage points; 95% CI, 5.1 to 19.3), corresponding to a relative risk of distant metastases in the radical-prostatectomy group of 0.57 (95% CI, 0.44 to 0.75; P<0.001) (Fig. 2 and Table 1).

PALLIATIVE TREATMENT

In all, 145 men in the radical-prostatectomy group and 235 in the watchful-waiting group received androgen-deprivation therapy. The cumulative incidence of the use of androgen-deprivation therapy at 18 years was 42.5% in the radical-prostatectomy group and 67.4% in the watchful-waiting group (a difference of 25.0 percentage points; 95% CI, 17.7 to 32.3), corresponding to a relative risk of the use of androgen-deprivation therapy in the radical-prostatectomy group of 0.49 (95% CI, 0.39 to 0.60; P<0.001). Other palliative treatments, such as radiation therapy, were less common in the radical-prostatectomy group than in the watchful-waiting group (49 vs. 63); 4 men in the radical-prostatectomy group underwent laminectomy because of metastases as compared with 9 in the watchful-waiting group. Chemotherapy was less frequently used in the radical-prostatectomy group (13 and 17 men, respectively) (Table 1, and Fig. S1 in the Supplementary Appendix).

The difference in the use of palliative treatment between the study groups increased with time. At 18 years of follow-up, approximately 60% of men in the watchful-waiting group, as compared with approximately 40% of men in the radical-prostatectomy group, had disease progression (with or without confirmed metastases) and received androgen-deprivation therapy and other palliative treatments. The pattern was the same in both age groups (Fig. 3).

OUTCOMES ACCORDING TO AGE AND RISK CATEGORY

Among men who were younger than 65 years of age, there was a significant absolute reduction in all three investigated end points: a reduction of 25.5 percentage points in overall mortality, 15.8 percentage points in death from prostate cancer, and 15.8 percentage points in the risk of metastases. In this age group, the number needed to treat to prevent one death from prostate cancer was 4.

Among men 65 years of age or older at diagnosis, there was no significant reduction in mortality, but there was a significant absolute reduction of 8.9 percentage points in the risk of metastases. In this age group, more men in the watchful-waiting group than in the radical-prostatectomy group died from prostate cancer or from causes other than prostate cancer, but with metastases present (52 men in the watchful-waiting group and 39 men in the radical-prostatectomy group). The P value for the interaction between age and treatment with respect to death from prostate cancer was 0.10.

Among men in the low-risk group, there was a significant absolute reduction in two of the three investigated end points: a reduction of 15.6 percentage points in the rate of death from any cause and 10.6 percentage points in the risk of metastases; the reduction of 3.8 percentage points in the rate of death from prostate cancer was not significant. Among men in the intermediate-risk group, there was a significant absolute reduction in all three end points: a reduction of 15.5 percentage points in overall mortality, 24.2 percentage points in the rate of death from prostate cancer, and 19.9 percentage points in the risk of metastases. Among men in the high-risk group, there was no significant reduction in absolute risk with respect to any of the end points. The P value for the interaction between tumor risk and treatment with respect to death from prostate cancer was 0.07 (Fig. 1 and 2 and Tables 1 and 2).

DISCUSSION

A significant absolute reduction in the rate of death from any cause, the rate of death from prostate cancer, and the risk of metastases in the radical-prostatectomy group continued after up to 23.2 years of follow-up (median, 13.4 years), with no evidence that these benefits diminished over time. In analyses according to age and tumor risk, the effects were more pronounced in men younger than 65 years of age and in men with intermediate-risk tumors. However, among men older than 65 years of age who underwent radical prostatectomy, there was a significantly decreased risk of metastases and need for palliative treatment. We observed a substantial difference in the prevalence of disease burden between the study groups.

In SPCG-4, the reduction in the rate of death...
attributed to radical prostatectomy increased with the number of years of follow-up, as shown by a relative reduction at 18 years of 44% and an increasing difference in rates of death from prostate cancer; this indicates that radical prostatectomy prevented deaths from tumors over a wide range of growth rates. Every third man who was assigned to watchful waiting had died from prostate cancer or from other causes, but with metastases present, whereas in the radical-prostatectomy group, every fifth man died. These results underscore the fact that our trial included men with tumors diagnosed before the advent of PSA screening. From 10 to 18 years of follow-up, the number needed to treat to prevent one death decreased from 20 to 8 in the whole cohort, and from 8 to 4 among men younger than 65 years of age.

At 18 years, the estimates of the risk of metastases and of death from other causes but with confirmed metastases were as follows:

**Figure 3. Prevalence of Metastases and Use of Palliative Treatment in Men Alive at Various Time Points since Randomization.**

The use of gonadotropin-releasing hormone (GnRH) analogues is considered to be medical castration, and orchiectomy is considered to be surgical castration.
disease progression indicate that older men with a long life expectancy benefit from radical prostatectomy. Older men may have more urinary leakage after surgery, but erectile dysfunction may not profoundly affect quality of life in older men, since many of them are less sexually active and have a greater burden of erectile dysfunction preoperatively.\textsuperscript{11-15}

Our analyses according to tumor risk aimed to provide evidence for the current debate about active surveillance. However, these analyses are merely hypothesis-generating: the numbers in each subgroup are low, and the risk categorization is less sophisticated than current standards. Given these caveats, the small absolute risk reduction in the rate of death from prostate cancer in the low-risk group at 18 years does not contradict current guidelines recommending active surveillance in men with low-risk prostate cancer.\textsuperscript{16} The modest reduction in absolute risk in the high-risk group differs from the results of the PIVOT study, which suggested a possible survival benefit only in men with intermediate-risk or high-risk tumors.\textsuperscript{2} However, there was evidence that a substantial proportion of men in the high-risk group in our trial had micrometastases at diagnosis (16 had lymph node–positive metastases), and therefore they did not undergo surgery. Thus, the difference between SPCG-4 and PIVOT may foremost reflect the different biologic domains of disease involved and possible differences in approaches to when to abstain from radical prostatectomy.

We used the prevalence of metastases and the use of palliative treatment as information about the burden of disease. As shown by previous studies\textsuperscript{12} and by the similar risk estimates associated with treatments for progressive disease and metastases, the use of palliative treatments in SPCG-4 closely followed the pattern of recurrent disease. A competing risk of cardiovascular deaths after androgen-deprivation therapy should therefore mainly be a problem among men with progressive disease. The finding that older men had an increased risk of death from causes other than prostate cancer may partly reflect this phenomenon. Metastases and the associated use of androgen-deprivation therapy are strongly associated with reduced quality of life.\textsuperscript{12,17} The life experience after the diagnosis of prostate cancer differs substantially between the two study groups and evolves over decades. Although the disease burden was large in the watchful-waiting group, a substantial proportion of men in this group did not have disease progression and did not receive palliative treatment. Therefore, there is a need to identify markers of aggressive disease.

One man died after surgery in the radical-prostatectomy group. Our follow-up to assess quality of life at a mean of 12.4 years showed a prevalence of erectile dysfunction of 84% in the radical-prostatectomy group and 80% in the watchful-waiting group; urinary leakage was reported in 41% and 11%, respectively. Distress from these symptoms was reported as being significantly greater in men assigned to radical prostatectomy than watchful waiting.\textsuperscript{14}

The strengths of our study include the randomized design, the completeness of follow-up, and the independent and blinded evaluation of the cause of death. Adherence to the assigned regimen was high. Our interpretation relies on estimates that are consistent over an extended follow-up. The subgroup analyses were not prespecified in the protocol and are exploratory and sensitive to chance findings and limited power.

Extended follow-up 23 years after the initiation of the study corroborated a substantial reduction in the rate of death after radical prostatectomy. The number needed to treat to prevent one death has continued to decrease. The hypothesis-generating subgroup analyses and the large proportion of long-term survivors in the watchful-waiting group who never required palliative treatment provide support for active surveillance as an alternative in adequately selected groups. However, the overall long-term disease burden is also a reminder that factors other than survival should be considered when counseling men with localized prostate cancer; the risk of metastases and ensuing palliative treatments also affect quality of life.

Supported by grants from the Swedish Cancer Society (07 05 12, to Dr. Johansson; and 09 05 12, to Dr. Bill-Axelson), the National Institutes of Health (1ROI CA 108746-O1A1, to Dr. Steineck), the Karolinska Institutet (distinguished professor award Dnr:2368/10-221, to Dr. Adami), and the Prostate Cancer Foundation and Percy Falk Foundation (both to Dr. Bill-Axelson).

No potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the authors with the full text of this article at NEJM.org.
REFERENCES


Copyright © 2014 Massachusetts Medical Society.